Petros Pharmaceuticals (PTPI) Competitors $0.03 0.00 (-8.88%) As of 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. INM, TTNP, PLRZ, EVOK, LIPO, DRMA, VIVS, CMND, CANF, and ARTLShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include InMed Pharmaceuticals (INM), Titan Pharmaceuticals (TTNP), Polyrizon (PLRZ), Evoke Pharma (EVOK), Lipella Pharmaceuticals (LIPO), Dermata Therapeutics (DRMA), VivoSim Labs (VIVS), Clearmind Medicine (CMND), Can-Fite BioPharma (CANF), and Artelo Biosciences (ARTL). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors InMed Pharmaceuticals Titan Pharmaceuticals Polyrizon Evoke Pharma Lipella Pharmaceuticals Dermata Therapeutics VivoSim Labs Clearmind Medicine Can-Fite BioPharma Artelo Biosciences InMed Pharmaceuticals (NASDAQ:INM) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends. Which has more risk and volatility, INM or PTPI? InMed Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Which has higher valuation & earnings, INM or PTPI? InMed Pharmaceuticals has higher earnings, but lower revenue than Petros Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInMed Pharmaceuticals$4.60M0.72-$7.68M-$12.09-0.23Petros Pharmaceuticals$5.11M0.19-$8.16M-$119.000.00 Is INM or PTPI more profitable? Petros Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. Petros Pharmaceuticals' return on equity of -78.22% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals-168.87% -107.93% -82.97% Petros Pharmaceuticals N/A -78.22%-23.50% Does the media refer more to INM or PTPI? In the previous week, InMed Pharmaceuticals had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for InMed Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.32 beat Petros Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment InMed Pharmaceuticals Neutral Petros Pharmaceuticals Neutral Do institutionals and insiders believe in INM or PTPI? 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 1.4% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryPetros Pharmaceuticals beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$991K$784.70M$5.45B$8.93BDividend YieldN/A4.84%5.22%4.01%P/E Ratio-0.011.3027.2420.06Price / Sales0.19230.50426.37117.54Price / CashN/A23.4426.2128.59Price / Book0.016.237.925.56Net Income-$8.16M-$27.94M$3.17B$248.56M7 Day PerformanceN/A2.21%4.40%7.56%1 Month PerformanceN/A8.98%2.64%8.54%1 Year PerformanceN/A11.57%35.04%21.81% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.6395 of 5 stars$0.03-8.9%N/A-99.7%$991K$5.11M-0.0120Gap UpINMInMed Pharmaceuticals1.0235 of 5 stars$3.25-3.8%N/A-44.9%$4.08M$4.60M-0.2710Analyst UpgradeGap DownTTNPTitan Pharmaceuticals0.0826 of 5 stars$4.20-4.5%N/A-14.6%$4.02M$180K-0.9210Gap UpPLRZPolyrizonN/A$0.740.0%N/AN/A$3.94MN/A0.00N/APositive NewsGap DownEVOKEvoke PharmaN/A$2.60-1.1%N/A-58.3%$3.92M$10.25M-0.914Positive NewsLIPOLipella Pharmaceuticals1.3154 of 5 stars$0.87-3.6%N/A-78.8%$3.88M$536.36K-0.214DRMADermata Therapeutics1.906 of 5 stars$0.59-3.2%$3.00+412.8%-71.8%$3.85MN/A-0.048Positive NewsGap UpVIVSVivoSim LabsN/A$1.47flatN/AN/A$3.82M$140K-0.1420Positive NewsCMNDClearmind Medicine0.6292 of 5 stars$0.90+1.2%N/A-30.5%$3.79MN/A-0.82N/ACANFCan-Fite BioPharma3.297 of 5 stars$1.05+1.0%$14.00+1,233.3%-57.9%$3.72M$674K-0.598ARTLArtelo Biosciences2.9572 of 5 stars$13.27+95.4%$33.00+148.7%+34.8%$3.71MN/A-0.745Gap UpTrading HaltedHigh Trading Volume Related Companies and Tools Related Companies InMed Pharmaceuticals Competitors Titan Pharmaceuticals Competitors Polyrizon Competitors Evoke Pharma Competitors Lipella Pharmaceuticals Competitors Dermata Therapeutics Competitors VivoSim Labs Competitors Clearmind Medicine Competitors Can-Fite BioPharma Competitors Artelo Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
